Literature DB >> 21624664

Reversion rates of QuantiFERON-TB Gold are related to pre-treatment IFN-gamma levels.

Kosaku Komiya1, Haruyuki Ariga, Hideaki Nagai, Atsuyuki Kurashima, Syunsuke Shoji, Hiroshi Ishii, Yutsuki Nakajima.   

Abstract

OBJECTIVE: The quantitative interferon (IFN)-gamma in response to Mycobacterium tuberculosis-specific antigens declines in tuberculosis patients after starting treatment, however, in some cases remains high despite clinical improvements. Our aim was to evaluate clinical parameters associated with remaining QuantiFERON-TB Gold (QFT-G) positive after treatment.
METHODS: A prospective cohort study of 101 culture-positive, positive QFT-G, HIV-uninfected patients with pulmonary tuberculosis. QFT-G was performed at diagnosis, at the end of intensive phase, at treatment completion, and 5-7 months post-treatment completion.
RESULTS: There were 80 patients with complete results, 34 (43%) remaining QFT-G positive and 46 (58%) reverting to QFT-G negative at the 5-7 month post-treatment time point. There was a significant decline in IFN-gamma levels in response to both CFP-10 and ESAT-6 with tuberculosis treatment. Multivariate analysis revealed significant associations between IFN-gamma levels detected before treatment and remaining QFT-G positive post-treatment after adjustment for smear status, presence of cavitation, and positive sputum culture two months after starting treatment.
CONCLUSIONS: Quantitative QFT-G responses drop significantly in active tuberculosis patients undergoing treatment, with almost 60% becoming test negative. Reversion to a negative QFT-G result was closely associated with the magnitude of the IFN-gamma response prior to treatment and increasing age.
Copyright © 2011 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21624664     DOI: 10.1016/j.jinf.2011.05.006

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  4 in total

1.  QuantiFERON-TB Gold In-Tube test conversions and reversions among tuberculosis patients and their household contacts in Addis Ababa: a one year follow-up study.

Authors:  Mulugeta Belay; Mengistu Legesse; Daniel Dagne; Adane Mihret; Yonas Bekele; Girmay Medhin; Gunnar Bjune; Fekadu Abebe
Journal:  BMC Infect Dis       Date:  2014-12-03       Impact factor: 3.090

2.  HIV patients with latent tuberculosis living in a low-endemic country do not develop active disease during a 2 year follow-up; a Norwegian prospective multicenter study.

Authors:  Nadine Durema Pullar; Harald Steinum; Johan Nikolai Bruun; Anne Ma Dyrhol-Riise
Journal:  BMC Infect Dis       Date:  2014-12-17       Impact factor: 3.090

3.  Serial Interferon-Gamma Release Assay (IGRA) Testing to Monitor Treatment Responses in Cases of Feline Mycobacteriosis.

Authors:  Jordan L Mitchell; Conor O'Halloran; Paul Stanley; Kieran McDonald; Paul Burr; Danièlle A Gunn-Moore; Jayne C Hope
Journal:  Pathogens       Date:  2021-05-26

4.  Evaluation of Humoral Immunity to Mycobacterium tuberculosis-Specific Antigens for Correlation with Clinical Status and Effective Vaccine Development.

Authors:  Mamiko Niki; Maho Suzukawa; Shunsuke Akashi; Hideaki Nagai; Ken Ohta; Manabu Inoue; Makoto Niki; Yukihiro Kaneko; Kozo Morimoto; Atsuyuki Kurashima; Seigo Kitada; Sohkichi Matsumoto; Koichi Suzuki; Yoshihiko Hoshino
Journal:  J Immunol Res       Date:  2015-10-19       Impact factor: 4.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.